UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 6, 2017
WAVE LIFE SCIENCES LTD.
(Exact name of registrant as specified in its charter)
| Singapore | 001-37627 | Not Applicable | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 8 Cross Street #10-00, PWC Building Singapore 048424 |
048424 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: +65 6236 3388
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure. |
From time to time, WAVE Life Sciences Ltd. (the “Company”), presents and/or distributes slides and presentations to the investment community at various industry and other conferences to provide updates and summaries of its business. On January 6, 2017, the Company updated its corporate presentation, which is available on the Investors & Media section of the Company’s website at http://ir.wavelifesciences.com/. This presentation is attached as Exhibit 99.1 and is incorporated by reference herein.
The information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 8.01 | Other Events. |
On January 6, 2017, the Company issued a press release providing an update on its pipeline. A copy of the press release is attached as Exhibit 99.2 to this Form 8-K and is incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 99.1 | Corporate presentation of WAVE Life Sciences Ltd., dated as of January 6, 2017 | |
| 99.2 | Press release issued by WAVE Life Sciences Ltd. on January 6, 2017 | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| WAVE LIFE SCIENCES LTD. | ||||
| Date: January 6, 2017 | /s/ Keith C. Regnante | |||
| Keith C. Regnante Chief Financial Officer | ||||
Corporate Presentation January 6, 2017 Exhibit 99.1
Forward Looking Statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, business strategies, development plans, regulatory activities, competitive position, potential growth opportunities, use of proceeds and the effects of competition are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of WAVE Life Sciences Ltd. (the “Company”) to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect the Company’s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, including those listed under Risk Factors in the Company’s Form 10-K and other filings with the SEC, some of which cannot be predicted or quantified and some of which are beyond the Company’s control. The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that the Company may face. Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
WAVE Life Sciences Overview Genetic medicines company developing targeted nucleic acid therapies for patients impacted by rare diseases Rationally designed nucleic acid therapeutics optimized by stereochemistry Three lead candidates initiating clinical trials in 2017 Six development programs by end of 2018 Core focus and expertise in neurological rare genetic diseases Strategic partnerships for non-core assets, addressing multiple therapeutic areas Proprietary R&D platform and advanced chemistry: a sustainable engine for future growth Cash runway into 2019
Founded Chiralgen (Japan) Takeshi Wada Ontorii (USA) Greg Verdine 2009 2013 WAVE Life Sciences Formed Paul Bolno joins as CEO 2015 Nasdaq Initial Public Offering WVE: 6.4m shares @ $16 License Tuschl ssRNAi 2016 2017 2018 Initiate Clinical Development for HD Programs Data readouts expected for 3 Lead Candidates in HD, DMD Foundation of Intellectual Property Manufacturing Capabilities Expanded Platform Expansion & Pipeline Development Entering Clinic in 2017 Pfizer Collaboration 5 Hepatic Targets GMP Manufacturing Facility Secured Initiate Clinical Development for DMD Program $196M Raised in 2015 WAVE Life Sciences Overview
WAVE Life Sciences R&D Exploratory Platform Core Neurology Portfolio Mid 2017 Mid 2017 2H 2017 Non-Core Portfolio
An enormous number of permutations exist, often resulting in over 500,000 different molecules in every dose (e.g., 219 Antisense and Exon Skipping) Rp Sp Rp or Sp Linker Nucleotide Uncontrolled PS Modifications Introduce Chiral Centers Nucleic Acid Therapeutics Traditional Approach
WAVE platform enables the rational design, optimization and production of nucleic acid therapeutics, beginning with the control of stereochemistry By controlling the orientation of the chiral linkages in phosphorothioate (PS) backbone modifications, WAVE is able to optimize the interaction between a nucleic acid therapy and various enzymes to improve pharmacology Precisely designing and securing sequence improves stability, potency, specificity, and immunogenicity Stereopure PS Linkages: PS Placement by design Controlled Rp Sp Nucleotide Nucleic Acid Therapeutics WAVE Foundational Chemistry Controlling PS Linkages of Stereoisomers
WAVE Optimized Isomers Stability Activity Immune Specificity WAVE Rational Design Antisense RNAi Exon skipping Target Sequence WAVE proprietary platform precisely controls oligonucleotide stereochemistry Enables the discovery of the rules governing nucleic acid based drug pharmacology Provides basis for rational design with potential to improve activity, stability, specificity and immunogenicity Unique ability to optimize pharmacology across the therapeutic class Simplifies drug development and improves predictability Compatible with 2’ modifications Conventional wisdom of small molecule drug discovery applied to nucleic acid therapeutics Assess Control Optimize Validate Design Identify WAVE Chemistry Platform WAVE Life Sciences Approach
Mipomersen WVE-2 WVE-3 WVE-5 WVE-7 WVE-6 WVE-4 WVE-1 Oligonucleotide remaining (%) Time (days) Rat liver homogenate Stability Activity WVE-5 WVE-7 WVE-3 Mipomersen WVE-4 WVE-6 WVE-2 WVE-1 Sequence ID Sequence (5’-3’) Mipomersen WVE-6 WVE-4 WVE-1 WVE-2 WVE-3 WVE-5 WVE-7 Target remaining (%) Time (minutes) RNase H cell free assay Sequence ID Sequence (5’-3’) Stereopure WAVE Mipomersen Isomers R&D Platform WAVE chemistry enables increased stability and activity
Specificity RNA (full length) ASO RNA 13-mer RNA 7-mer RNA (full length) ASO 2.35min: 7mer 3.16min: 8mer, P-6mer 4.58min: P-7mer 5.91min: P-8mer 7.19min: 12mer 9.55min: 13mer 10.13min: P-11mer 11.14min: P-12mer, 14mer 12.11min: P-13mer 13.29min: P-14mer Others 2.45min: P-7mer 13.14: 13-mer Stereorandom WAVE stereopure Multiple cleavage sites Single defined cleavage site " Mass spectrograph R&D Platform WAVE chemistry allows highly specific targeting
Immunogenicity CpG, 5mC, MOE Same modifications with optimized stereochemistry CpG, 5mC, MOE CpG, 5mC, MOE Human TLR9 assay PBMC IL-6 activation PBMC MIP-1b activation Conventional wisdom: 5-methyl C (5mC) and 2’ modification is sufficient to avoid immune activation However, substantial immune activation exists within highly stable compounds despite the incorporation of these modifications WAVE chemistry platform enables reduced activation of the immune system Human TLR9 reporter assay and human PBMC cytokine panel (IL-6 and MIP-1b are key cytokines in B-cell and macrophage activation, respectively) R&D Platform Stereochemistry impacts immunogenicity
WAVE Stereochemistry Patents Granted and Pending Foundational Chemistry Chiral Control and Design Platform Candidate Specific IP Co-exclusive license holder for single-strand RNAi (ssRNAi) patent estate Martinez J, Patkaniowska A, Urlaub H, Lührmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 2002;110:563–574. License includes 19-29 nucleotides molecules; RNAi mechanism; various chemical modifications License to Pfizer hepatic targeting technology WAVE Intellectual Property
In June 2015, WAVE became the co-exclusive license holder (with Ionis Pharmaceuticals) to the single-strand RNAi patent estate (Tuschl, Zamore) Includes 19-29 nucleotides molecules; RNAi mechanism; various chemical modifications Single-stranded RNAi requires different design rules from double-stranded RNAi formats When properly optimized, single-stranded RNAi has comparable or greater potency than double-stranded RNAi formats Stereopure modifications are expected to provide further enhancements to pharmacology Martinez J, Patkaniowska A, Urlaub H, Lührmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 2002;110:563–574. “Considering the feasibility of modulating the stability and uptake properties of single-stranded RNAs, 5′-phosphorylated single-stranded antisense siRNAs may further expand the utility of RNAi-based gene silencing technology as tool for functional genomics as well as therapeutic applications.” Single Strand RNAi New modalities
Continue to meet demand IND enabling studies GMP clinical trial supply Comparable cost of goods Potential cost-per-patient advantages (dose and schedule) Scalable Synthesis Superior Pharmacology Applicable Across Modalities Rational design of single drugs Increased activity Increased stability Increased specificity Reduced immune activation Compatible with targeting moieties (GalNAc, others) Other areas in development Antisense (RNase H) Exon skipping RNAi single-strand (Ago2) Guide-strand (CRISPR) Genetic medicines toolkit Other areas in development WAVE Advantages Summary
Huntingtin Gene (HTT) Expanded CAG repeat Wild-type (healthy) allele Mutant allele SNP associated with expanded CAG repeat SNP Enables targets for allele-specific silencing 100% 75% 25% 0% 1 2 3 4 Targeted SNP HD Patients covered Cumulative HD Patient Coverage ~80% 50% ~77% ~71% ~55% Background Autosomal dominant disorder, characterized by chorea, psychiatric illness and cognitive decline Expanded CAG triplet repeat in HTT gene results in production of mutant HTT (mHTT) protein; accumulation of mHTT causes progressive loss of neurons in the brain1 Approximately 30,000 individuals have symptomatic HD in the United States No approved disease-modifying therapies available Wild type (healthy) HTT protein critical for neuronal function, and suppression may have detrimental long-term consequences2-8 WAVE Approach Lower mHTT gene transcript alone, while leaving healthy HTT relatively intact Target single nucleotide polymorphisms (SNPs) associated with mHTT gene to provide an approach to allele-specific gene silencing9 Huntington’s Disease (HD) 1Sturrock A, Leavitt BR. J Geriatr Psychiatry Neurol. 2010;23:243-259. 2Auerbach W, et al. Hum Mol Genet. 2001;10:2515-2523. 3Dragatsis I, et al. Nat Genet. 2000;26:300-306. 4Leavitt BR, et al. J Neurochem. 2006;96:1121-1129. 5Nasir J, et al. Cell. 1995;81:811-823. 6Reiner A, et al. J Neurosci. 2001;21:7608-7619. 7White JK, et al. Nat Genet. 1997;17:404-410. 8Zeitlin S, et al. Nat Genet. 1995;11:155-163. 9Carroll JB, et al. Mol Ther. 2011;19:2178-2185.
Huntington’s Disease WVE-120101 Selectively Cleaves mHTT RNA Reduced Complement Immune Response Selective Knockdown of mHTT Allele
Huntington’s Disease WVE-120101 Selectively Reduces mHTT mRNA and Protein
Stereochemistry enables improved protein binding and distribution ViewRNA depicting perinuclear distribution of WVE-120101 (red) in non-human primate (NHP) deep gray matter structures following intrathecal administration WVE-120101 detectable in deep gray matter structures following intrathecal administration Huntington’s Disease Distribution of WVE-120101 in Cynomolgus NHP Brain Animal # 42, Slice 8 Red dots are WVE-120101. Arrow points to nuclear and perinuclear distribution of WVE-120101 in deep gray matter structures In Situ Hybridization ViewRNA stained tissue
Source: Wild E, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J Clin Invest. 2015:125:1979–1986. Edward Wild, MA MB BChir PhD MRCP Principal Investigator at UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, London Novel immunoassay allows for selective detection of mutant huntingtin in CSF Level of mHTT detected associated with time to onset, diminished cognitive and motor function Advancements in Huntington’s disease research allow for better quantification and measurement of mutant huntingtin Huntington’s Disease Single Molecule Counting mHTT
Refile IND for WVE-120101 and file IND for WVE-120102 in 1H 2017 with updated clinical protocols, accelerating time to multi-ascending dose (MAD) studies and potentially reducing time to proof-of-concept (POC) Updated plan informed by discussions with the FDA and new supportive data from multi-dose animal toxicology studies Updated plan includes moving straight to two simultaneous multi-ascending-dose (MAD) studies, potentially accelerating time to proof-of-concept Clinical Trial Applications in Europe on track for 1H 2017 First-in-patient dosing for both WVE-120101 (SNP-1) and WVE-120102 (SNP-2) trials expected mid-year 2017 20 Huntington’s Disease Clinical Development Update
1 Updated Clinical Trial Design for WVE-120101 and WVE-120102 Two parallel global placebo-controlled MAD trials targeting SNP-1 and SNP-2, respectively Primary Objective: Assess safety and tolerability of intrathecal doses in early manifest HD patients Additional Objectives: Exploratory pharmacokinetic, pharmacodynamic, clinical and MRI endpoints Patient SNP determination (SNP-1, SNP-2, other) at pre-screening visit Approximately 60 patients per trial Key inclusion criteria: Age ≥25 to ≤65, Stage I or Stage II Huntington’s disease Huntington’s Disease Clinical Development Update
Pre-mRNA mRNA Protein Pre-mRNA mRNA Protein Exon skipping (Potential Remedy) WAVE oligonucleotide skip Disrupted reading frame Restored reading frame Dysfunctional splicing (Disease) The Disease Fatal X-linked genetic neuromuscular disorder caused by reduction of functional dystrophin 1 in 3,500 boys worldwide are born with DMD of which 13% carry mutations in Exon 51 Our Approach Partial restoration of dystrophin production is expected to result in therapeutic benefit Exon-skipping antisense approaches may enable production of functional dystrophin protein WAVE stereopure chemistry has potential to address limitations of current approaches Duchenne Muscular Dystrophy (DMD)
RNA skipping determined by quantitative RT-PCR WAVE isomers demonstrated a dose-dependent increase in skipping efficiency Dose Response on Skipping Efficiency (mRNA, in vitro) (4 Days) 10uM used for DMD protein restoration Western Blot Duchenne Muscular Dystrophy
Enhanced Protein Restoration using WAVE Chemistry (10uM, 6 Days) Skeletal Muscle Tissue lysates Marker Mock Drisapersen Eteplirsen WV-isomer 1 WV-isomer 2 WV-isomer 3 dystrophin (400-427 kDa) Vinculin (120 kDa) DMD protein restoration by Western Blot in patient-derived myotubes Free uptake at 10uM concentration of each compound with no transfection agent Extent of dystrophin protein restoration in vitro was quantified to be between 50-100% of normal skeletal muscle tissue lysates, as compared to about 1% by drisapersen or eteplirsen at this concentration Duchenne Muscular Dystrophy
Fold Increase of DMD Protein Restoration Compared to Eteplirsen Percentage of DMD Protein Restoration Compared to Normal Skeletal Muscle Duchenne Muscular Dystrophy
Candidate selected for DMD Exon 51, WVE-210201 (WV-isomer 1) Clinical trials on track to initiate 2H 2017 Protocol development in collaboration with DMD community Trials to include ambulatory and non-ambulatory patients Patients previously treated with other exon skipping therapies will not be excluded Measurement of dystrophin via standardized Western Blot Initiation of GMP manufacturing Duchenne Muscular Dystrophy Clinical Development Update
27 GMP manufacturing facility leased in Lexington, MA Increases control and visibility of our manufacturing supply chain, with potential commercial-scale capabilities by 2019 90,000 square foot facility to support future growth Supplements existing Cambridge headquarters and facilities Facility expected to be occupied 2Q 2017 WAVE Manufacturing Capabilities
2017 Upcoming Catalysts Initiating Three Clinical Programs in 2017 Initiate two clinical trials in Huntington’s disease mid-2017 Potential to be first two allele-specific disease-modifying therapies Initiate clinical trial in DMD 2H 2017 First stereopure oligonucleotide targeting Exon 51 with potential to be best-in-class Nominate three additional proprietary therapeutic candidates to progress to clinic Initiate in-house GMP production of stereopure oligonucleotide candidates 28
Exhibit 99.2
WAVE Life Sciences 2017 Pipeline Update
Three Lead Neurology Programs to Enter Clinic in 2017
CAMBRIDGE, Mass., January 6, 2016 – WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced updates to its clinical pipeline for 2017.
“2017 will be an important year for WAVE as we transition our two lead candidates in Huntington’s disease and our exon-skipping candidate in Duchenne Muscular Dystrophy into clinical trials,” said Paul Bolno, M.D., MBA, President and Chief Executive Officer of WAVE Life Sciences. “Furthermore, we plan to select three additional proprietary candidates this year which will keep us on track to initiate six development programs by the end of 2018, each with the potential to make a meaningful impact to patients with rare genetic diseases.”
Updated clinical development plan for lead Huntington’s disease (HD) programs WVE-120101 and WVE-120102
Informed by discussions with the FDA and with supportive interim data from ongoing multi-dose toxicology studies, WAVE intends to refile its Investigational New Drug (IND) Application for WVE-120101 (SNP-1) and to file its IND for WVE-120102 (SNP-2) in the first half of 2017. The company’s initial plan was to complete a single-ascending-dose phase prior to initiation of the multi-dose portion of the trial. With the updated trial design, the company intends to move straight to two simultaneous multi-ascending-dose (MAD) studies, potentially accelerating time to proof-of-concept.
As part of the company’s HD global development strategy, WAVE remains on track to file a Clinical Trial Application (CTA) in Europe in the first half of 2017. Both SNP-1 and SNP-2 allele-specific HD programs are expected to enter the clinic in mid-2017.
WVE-120101 and WVE-120102 each target a distinct patient population, which together account for over two-thirds of the HD population. Each therapeutic candidate is designed to selectively silence mRNA transcript produced by the disease-causing mutant huntingtin (HTT) allele in order to reduce the mutant HTT protein while leaving the healthy HTT allele intact to produce normal functioning protein. If approved, WVE-120101 and WVE-120102 would be the first allele-specific therapies for Huntington’s disease patients. Huntington’s disease is an autosomal dominant genetic disorder, involving the HTT gene, characterized by chorea, psychiatric illness and cognitive decline. HD is a devastating condition that is invariably fatal affecting over 30,000 symptomatic individuals in the United States alone, with no approved disease-modifying therapies currently available.
Duchenne Muscular Dystrophy program entering clinic in 2H 2017
WAVE has selected its stereopure exon-skipping candidate, WVE-210201, to target deletions of Exon 51. Pre-clinical quantitative Western blot studies of WAVE’s DMD Exon 51 candidate demonstrated 52% dystrophin protein restoration as compared with normal skeletal muscle tissue lysates, versus approximately 1% when testing other exon-skipping therapies. WAVE is developing clinical trial protocol in collaboration with the DMD community and intends to include both ambulatory and non-ambulatory the patients in the study as well as those previously treated with other exon skipping therapies. GMP manufacturing is underway to support planned clinical trials to ensure adequate supply for current and planned studies. The company is on track to initiate a global clinical program in the second half of 2017.
Continued progress unlocking value in adjacent therapeutic areas
WAVE continues to make progress under its collaboration with Pfizer to develop genetically targeted therapies for the treatment of metabolic diseases, including NASH and NAFLD, with three programs advancing through lead-optimization, including ApoC-III programs. The collaboration leverages WAVE’s stereochemistry platform across antisense and RNAi modalities and incorporates GalNAc and Pfizer’s hepatic targeting technology. The remaining two Pfizer collaboration programs are expected to commence by November 2017.
1
Establishing internal GMP manufacturing capabilities
To provide internal GMP manufacturing capabilities and increase control and visibility of our manufacturing supply chain, WAVE recently signed a lease for a manufacturing facility of approximately 90,000 square feet in Lexington, MA. This new facility supplements WAVE’s existing Cambridge, MA headquarters, supports growth and secures availability of drug product for current and future development activities and potential commercial-scale manufacturing.
About WAVE Life Sciences
At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize rationally redesigned nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com.
Forward Looking Information
This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following: the anticipated timing of our IND filings and the commencement of our clinical trials; the design and anticipated goals of our clinical trials; the future performance and results of our programs in clinical trials; the progress and potential benefits of our collaborations with partners; our identification of future candidates and their therapeutic potential; the anticipated therapeutic benefits of stereopure therapies compared to other therapies; our advancing of therapies across multiple modalities and the anticipated benefits of that strategy; our future growth; and the potential of our stereopure approach and nucleic acid therapeutics generally. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the following: the ability of our preclinical programs to produce data sufficient to support the filing of INDs and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results of our programs, which may not support further development of product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical studies; our effectiveness in managing future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to raise additional capital as needed; and competition from others developing therapies for similar uses, as well as the information under the caption “Risk Factors” contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 30, 2016 and in other filings we make with the SEC. We undertake no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
Media and Investor Contact:
WAVE Life Sciences
Jillian Connell, Head of Investor Relations
617-949-2981
jconnell@wavelifesci.com
2